Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,040Revenue $M49.0Net Margin (%)12.2Z-Score0.4
Enterprise Value $M1,046EPS $0.6Operating Margin %29.2F-Score6
P/E(ttm))167Cash Flow Per Share $0.6Pre-tax Margin (%)11.2Higher ROA y-yN
Price/Book24.010-y EBITDA Growth Rate %0Quick Ratio10.7Cash flow > EarningsY
Price/Sales20.15-y EBITDA Growth Rate %0Current Ratio10.8Lower Leverage y-yN
Price/Cash Flow32.1y-y EBITDA Growth Rate %27.1ROA % (ttm)5.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)8ROE % (ttm)12.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M19.9ROI % (ttm)10.2Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 52.960%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 52.96-19%New holding, 55492 sh.55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 52.96-19%New holding, 36908 sh.36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 52.96-20%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 52.961%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 52.9617%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 52.96315%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 52.96302%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 52.96402%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 52.96402%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 52.96339%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 52.96226%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Joel Greenblatt 2014-09-30552,0532.780.26+894.83%
LGND Ken Fisher 2014-09-3035,2580.180-4.47%
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6815.94view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9117.92view
KNOTT DAVID MDirector 2014-10-09Buy4,000$43.0123.13view
Sabba Stephen LDirector 2014-10-09Buy2,000$43.1222.82view
Aryeh JasonDirector 2014-10-09Buy11,000$42.9923.19view
HIGGINS JOHN LPresident & CEO 2014-08-15Buy1,000$54.97-3.66view
FOEHR MATTHEW WEVP and COO 2014-06-30Buy428$43.7920.94view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-06-30Buy329$43.7920.94view
Herman Melanie JDirector of Accounting 2014-06-30Buy98$43.7920.94view
Herman Melanie JDirector of Accounting 2014-06-09Sell1,100$69.68-24view

Press Releases about LGND :

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 

More From Other Websites
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for... Dec 26 2014
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for... Dec 26 2014
7:30 am Ligand Pharma announces submission of New Drug Application for Captisol-Enabled Melphalan Dec 26 2014
Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™... Dec 26 2014
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
LIGAND PHARMACEUTICALS INC Financials Dec 19 2014
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated... Dec 19 2014
Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated... Dec 19 2014
10-K/A for Ligand Pharmaceuticals, Inc. Dec 14 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report Dec 12 2014
10-K/A for Ligand Pharmaceuticals, Inc. Dec 03 2014
Coverage initiated on Ligand Pharma by Deutsche Bank Dec 02 2014
UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On... Dec 02 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report Dec 01 2014
Lemelson Capital Management CIO Discusses Ligand Pharmaceuticals Prior To Company Issuing Weak... Nov 18 2014
Ligand Provides Highlights from Today’s Analyst Day Event Nov 18 2014
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Nov 18 2014
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug Nov 13 2014
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
10-Q for Ligand Pharmaceuticals, Inc. Nov 03 2014
LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Oct 31 2014
Twitter gives out 47% of its revenue in stock bonuses Oct 29 2014
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss Oct 29 2014
Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
Ambaraella, Pier One, Pfizer, Teva Pharmaceutical and Ligand Pharmaceuticals highlighted as Zacks... Oct 27 2014
Ligand beats Street 3Q forecasts Oct 27 2014
Ligand beats Street 3Q forecasts Oct 27 2014
Ligand to Report Third Quarter 2014 Financial Results Oct 27 2014
Ligand to Host Analyst Day on November 18th in New York City Oct 16 2014
Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL®... Mar 17 2014
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference Mar 11 2014
Captisol® Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV Mar 10 2014
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta® (eltrombopag) for... Feb 28 2014
Ligand to Present at the 26th Annual Roth Conference on March 11 Feb 28 2014
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results Feb 11 2014
Ligand to Receive $1 Million Kyprolis® Commercial Milestone Payment from Onyx Pharmaceuticals Feb 10 2014
Ligand, Glaxo drug gets special FDA designation Feb 03 2014
Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade®... Feb 03 2014
Ligand to Report Fourth Quarter Results on February 11th Jan 29 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK